Gene Logic Plans Sale of Genomics Division; Touts Progress in Drug Repositioning Effort | GenomeWeb
Gene Logic said last week that it is planning to sell its genomics division and focus its resources on becoming a pharmaceutical development company based on its drug repositioning business.
In line with that strategy, the company for the first time provided information about the progress of its drug repositioning effort, disclosing that a candidate licensed from Millennium showed efficacy “at relevant doses” in in vivo testing for inflammatory bowel disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.